Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Long-term outcomes of neoadjuvant DCF in locally advanced ESCC

Ken Kato, MD, PhD, National Cancer Center Hospital East, Tokyo, Japan, discusses the 5-year follow-up results from the JCOG1109 study (jRCTs031180202) of neoadjuvant 5- fluorouracil plus cisplatin (CF) with or without docetaxel (DCF) in patients with locally advanced esophageal squamous cell cancer (ESCC). Addition of docetaxel significantly improved overall survival (OS) and progression-free survival (PFS). The study highlights sustained clinical benefits and manageable safety profile of CF with docetaxel. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.